MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says ArtemiC, its nutraceutical food supplement designed to support the immune system, has received regulatory approval for sale in Germany. Says ArtemiC successfully underwent a Phase II clinical trial in 2020, which demonstrated efficacy in improving and expediting the clinical recovery of patients with mild Covid-19.
Separately, says as part of the registration process for CimetrA in India, an observational open label controlled clinical trial of its sister product ArtemiC, showed the formulation demonstrated its efficacy in the treatment of patients with severe Covid-19 for the first time.
Says findings from observational trial expands potential use of CimetrA and ArtemiC to treat patients with severe Covid-19, and further supports previous preclinical and clinical findings for patients with moderate Covid-19, both of which assist placing CimetrA as an anti-inflammatory agent.
Current stock price: 3.44 pence
Year-to-date change: up 44%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.